BioSenic

Active

Public limited companyfounded 2006active for 20 yearsAvenue Léon Champagne 3, 1480 Tubize, BelgiumKBO/BCE: BE 0882.015.654

Summary

BioSenic has been active since 2006 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (-€661,415) and a net result of €22.2m. Equity is shrinking by about 25% per year across the filed financial years. Its solvency ranks better than 9% of 237 sector peers (NACE 72, financial year 2025). The computed 12-month bankruptcy probability is 0.5% (very low).

Risk analysisFollow Report Compare

BioSenicActiveChecked score 55/100

Risk analysis Report Compare

Group and network

Heads the group BioSenic 2 companies Group, risk and exposure

Holdings and subsidiaries

1 holding

Holdings 1

SKELETAL CELL THERAPY SUPPORT, EN ABREGE : SCTSsubsidiary
SourceLEI register

consolidated

According to the 2025 annual accounts of BioSenic and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.